EPSRC Centre for Doctoral Training in Emergent Macromolecular Therapies (EMT): A National CDT linked to an EPSRC Centre for Innovative Manufacturing

EPSRC 紧急大分子疗法 (EMT) 博士培训中心：与 EPSRC 创新制造中心相关的国家 CDT

• 批准号: EP/L015218/1
• 金额: $ 478.14万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Training Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FL015218%2F1
• 关键词: EPSRC; Centre; Doctoral; Training; Emergent

The bioprocess industry manufactures novel macromolecular drugs, proteins, to address a broad range of chronic and debilitating human diseases. The complexity of these protein-based drugs brings them significant potential in terms of potency against disease, but they are also much more labile and challenging to manufacture than traditional chemical drugs. This challenge is continuing to increase rapidly as novel technologies emerge and make their way into new therapies, such as proteins conjugated to chemical drug entities, DNA, RNA or lipids, or fusions of multiple proteins, which increase their potency and targeted delivery in patients. The UK holds a leading position in developing and manufacturing new therapies by virtue of its science base and has unique university capabilities underpinning the sector. Whilst revenues are large, ~£110bn in 2009 on a worldwide basis, there are huge pressures on the industry for change if demands for healthcare cost reduction and waste minimisation are to be met, and populations are to benefit from the most potent drugs becoming available. A sea change in manufacturing will be needed over the next decade if the potential of modern drugs are to make their way through to widespread distribution. Moreover there is a widely accepted skills shortage of individuals with fundamental "blue-skies" thinking capability, yet also with the manufacturing research training needed for the sector. The proposed EPSRC CDT will deliver a national capability for training the next generation of highly skilled future leaders and bioprocess manufacturing researchers for the UK biopharmaceutical sector. They will be capable of translating new scientific advances both in manufacturing technologies and new classes of macromolecular products into safely produced, more selective, therapies for currently intractable conditions at affordable costs. This is seen as essential where the rapid evolution of biopharmaceuticals and their manufacturing will have major implications for future medicine. The CDT will be a national resource linked to the EPSRC Centre for Innovative Manufacturing (CIM) in Emergent Macromolecular Therapies (EP/I033270/1), which aims to tackle new process engineering, product stability, and product analysis challenges that arise when manufacturing complex therapies based on radically new chemistry and molecular biology. The CDT will embed PhD students into the vibrant research community of the top UK Institutions, with collaborations overseen by the EPSRC CIM, to enable exploration of new process engineering, modelling, analysis, formulation and drug delivery techniques, and novel therapies (e.g. fusion proteins, and chemical drugs conjugated to antibodies), as they emerge from the international science and engineering community. Alignment to the EPSRC CIM will ensure projects strategically address key bioprocess manufacturing challenges identified by the industrial user group, while providing a cohort-based training environment that draws on the research excellence of the ESPRC CIM to maximise impact and knowledge transfer from collaborative partners to research led companies.

生物加工工业生产新型大分子药物——蛋白质，用于治疗多种慢性和衰弱性人类疾病。这些蛋白质药物的复杂性为它们带来了对抗疾病的巨大潜力，但它们也更加不稳定和具有挑战性。随着新技术的出现并进入新的治疗方法，例如与化学药物实体、DNA、RNA 或脂质缀合的蛋白质，或多种蛋白质的融合，这一挑战正在迅速增加。效力和英国凭借其科学基础和独特的大学能力在新疗法的开发和制造方面处于领先地位，尽管2009年全球收入约为1100亿英镑。如果要满足降低医疗保健成本和最大限度减少废物的要求，并且要让人们从最有效的药物中受益，如果现代技术的潜力得到发挥，那么在未来十年内，制造业将需要发生巨大的变化。毒品将大行其道此外，人们普遍认为缺乏具有基本“蓝天”思维能力的人才，但拟议的 EPSRC CDT 将提供国家培训下一代的能力。为英国生物制药行业培养高技能的未来领导者和生物工艺制造研究人员，他们将能够将制造技术和新型大分子产品方面的新科学进步转化为以可承受的成本安全生产、更具选择性的疗法。 。这是当生物制药及其制造的快速发展将对未来医学产生重大影响时，CDT 将成为与 EPSRC 新兴大分子疗法创新制造中心 (CIM) 相关的国家资源 (EP/I033270/1)，该项目旨在解决基于全新化学和分子生物学制造复杂疗法时出现的新工艺工程、产品稳定性和产品分析挑战，CDT 将让博士生参与到充满活力的研究中。由英国顶级机构组成的社区，在 EPSRC CIM 的监督下进行合作，以探索新的工艺工程、建模、分析、配方和药物输送技术以及新疗法（例如融合蛋白和与抗体缀合的化学药物），他们来自国际科学和工程界，与 EPSRC CIM 的结合将确保项目战略性地解决工业用户群体确定的关键生物工艺制造挑战，同时提供基于群体的培训环境，借鉴该领域的卓越研究成果。 ESPRC CIM 旨在最大限度地提高合作伙伴对研究主导公司的影响和知识转移。